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Abstract
We studied telomere length in 32 CML patients who discontinued imatinib after achieving complete molecular
remission and 32 age-sex-matched controls. The relative telomere length (RTL) was determined by q-PCR as the
telomere to single copy gene (36B4) ratio normalized to a reference sample (K-562 DNA). Age-corrected RTL (acRTL)
was also obtained. The 36-month probability of treatment-free remission (TFR) was 59.4 %. TFR patients showed
shorter acRTL compared to relapsed (mean ± SD = 0.01 ± 0.14 vs 0.20 ± 0.21; p = 0.01). TFR was significantly higher in
CML patients with acRTL ≤0.09 (78.9 vs 30.8 %, p = 0.002). CML stem cells harboring longer telomeres possibly
maintain a proliferative potential after treatment discontinuation.
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Telomeres are specialized nucleoprotein structures com-
posed of long arrays of TTAGGG repeats localized at
the ends of human chromosomes able to maintain gen-
ome stability and integrity and to protect the cell from
progressive DNA shortening during repeated division
[1]. Telomere biology has been more extensively studied
in chronic myeloid leukemia (CML) than in any other
blood cancer. Shorter telomeres have been associated
with CML, disease progression, poor prognosis, higher
Hasford score, and acquisition of cytogenetic aberrations
[2–4]. As yet, no studies have considered the possible as-
sociation between telomere length and treatment-free
remission (TFR) after discontinuation of therapy with
tyrosine kinase inhibitors (TKIs).
Thirty-two chronic-phase CML patients discontinued
TKI treatment after achieving complete molecular re-
mission (CMR) for at least 18 months. All patients re-
ceived imatinib therapy for more than 24 months. Two
patients underwent second-line treatment with nilotinib
because of molecular relapse. The median follow-up
after discontinuation was 30 months (range 18–60). A
complete molecular response was defined as undetect-
able breakpoint cluster region-Abelson (BCR/ABL1) by
real-time quantitative polymerase chain reaction (qRT-
PCR) with a sensitivity of the assay corresponding to
molecular response (MR)4 and MR4.5. Peripheral blood
samples from 32 age- and sex-matched healthy individ-
uals were used for control purposes. The relative telo-
mere length (RTL) was determined by q-PCR according
to the technique described by Cawthon in 2002 [5]
(Additional file 1). Age-corrected RTL (acRTL) repre-
sented the difference in telomere length between
patients and age- and sex-matched controls.
The characteristics of 32 chronic phase CML patients
are shown in Table 1. Thirteen patients (41 %) showed
loss of CMR. All relapsed patients regained CMR after
restarting treatment with TKIs. The 36-month cumula-
tive probability of TFR was 59.4 %. RTL was assessed
at a mean of 26 months from discontinuation (range
20–30). RTL was assessed at a mean of 26 months
from discontinuation (range 18–30). The majority of
relapses occurred within 9 months of therapy inter-
ruption (mean 8.7 months, range 2–20). In these
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patients, RTL was assessed after relapse. Overall, median
RTL was slightly shorter in patients than in controls (0.97
vs 1.05). The median value of acRTL in the CML cohort
was 0.09 (range −0.26, +0.86). The Mann-Whitney U test
showed shorter acRTL in TFR patients compared to
patients with molecular relapse (mean ± SD = 0.01 ± 0.14
vs 0.20 ± 0.21; p = 0.01) (Additional file 2). Although the
male gender was more frequent in TFR patients, we did
not find any significant difference in telomere length
between male and female. Patients were stratified accord-
ing to the median value of acRTL ≤0.09. TFR was signifi-
cantly higher in CML patients with acRTL ≤0.09 in
comparison to those with longer telomeres (78.9 vs
30.8 %, p = 0.002) (Fig. 1).
Previous studies suggest a dual-step model for telo-
mere length changes in CML. In the earlier phases,
increased turnover of Philadelphia positive (Ph+) pro-
genitors would result in telomere shortening, leading to
genetic instability. Later, CML cells would escape senes-
cence and apoptosis through upregulation of telomerase
and restored telomere length. This would promote the
occurrence of genetically unstable CML subclones with
a selective growth advantage [6]. Discontinuation of
TKIs is the next hurdle to be overcome in the manage-
ment of CML patients. Several factors have been identi-
fied as potentially capable of predicting durable TFR and
hopefully definitive recovery [7, 8]. A significant correl-
ation between younger age and molecular relapse was
reported [9]. In our study, CML patients had a slightly
shorter telomere length than healthy controls and we
found a statistically significant correlation between aging
and telomere shortening. However, the most interesting
finding was that TFR patients showed significantly
shorter acRTL compared to molecular relapses. A pos-
sible explanation is that quiescent CML stem cells
harboring longer telomeres somehow manage to escape
senescence mechanisms and maintain a proliferative
Table 1 Characteristics of 32 CML patients according to treatment-free remission (TFR) or molecular relapse after imatinib
discontinuation
Patients in TFR no. 19 (59 %) Relapsed patients no. 13 (41 %) p
Age at diagnosis (mean, range) 74 (47–88) 56 (37–77) 0.004
Leukocytes at diagnosis ×103/uL (mean, range) 50.47 (8.15–221) 69 (19.8–263) ns
Platelets at diagnosis ×103/uL (mean, range) 472 (178–918) 357 (171–695) ns
Months to CMR (median, range) 28 (3–88) 30 (6–93) ns
Months of TKIs (median, range) 86 (24–127) 84 (45–143) ns
Months of TKIs >60 (no., %) 13 68.4 12 92.3 ns
Male gender (no., %) 16 84.2 8 61.5 ns
Sokal risk (no., %)
Low 6 31.6 8 61.5 ns
Intermediate 10 52.6 3 23.1 ns
High 3 15.8 2 15.4 ns
First-line TKI treatment (no., %) 11 57.9 11 84.6 ns
Previous IFN treatment (no., %) 8 42.1 2 15.4 ns
Imatinib first-line TKI treatment (no., %) 19 100 13 100 ns
Nilotinib second-line TKI treatment (no., %) 1 5.3 1 7.7 ns
Age-corrected relative telomere length (mean ± SD) 0.01 ± 0.14 0.20 ± 0.21 0.01
pres present, CMR complete molecular response, TKIs tyrosine kinase inhibitors, IFN interferon, ns not significant, SD standard deviation
Fig. 1 Treatment-free remission (TFR) according to age-corrected
relative telomere length (acRTL) ≥0.09 in 32 CML patients
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potential even after discontinuation of imatinib treat-
ment, but this hypothesis should be supported by CML
stem cell telomere assessment in patients with molecular
response. Some limitations need to be noted in our
study. First, the cohort of patients was relatively small
and a longitudinal telomere assessment from diagnosis is
lacking. Furthermore, we did not determine sorted mye-
loid compartment telomere length, but previous reports
showed that no significant differences in CML telomere
lengths are observed when comparing peripheral mono-
nuclear blood cells, fractionated peripheral neutrophils,
and non-fractionated bone marrow mononuclear cells
[10]. The present study is the first to suggest that
patients with longer telomeres would seem to be more
susceptible to relapse after TKI treatment.
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